Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RPS6KA1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RPS6KA1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RPS6KA1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RPS6KA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RPS6KA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004592710 | Oral cavity | OSCC | positive regulation of growth | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
GO:002261214 | Oral cavity | OSCC | gland morphogenesis | 62/7305 | 118/18723 | 1.91e-03 | 8.94e-03 | 62 |
GO:2000116110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity | 109/4623 | 235/18723 | 3.16e-13 | 2.91e-11 | 109 |
GO:0043281110 | Oral cavity | LP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 99/4623 | 209/18723 | 7.89e-13 | 6.68e-11 | 99 |
GO:0052547110 | Oral cavity | LP | regulation of peptidase activity | 177/4623 | 461/18723 | 3.01e-11 | 2.00e-09 | 177 |
GO:0052548110 | Oral cavity | LP | regulation of endopeptidase activity | 164/4623 | 432/18723 | 4.33e-10 | 2.20e-08 | 164 |
GO:0006417110 | Oral cavity | LP | regulation of translation | 175/4623 | 468/18723 | 4.49e-10 | 2.22e-08 | 175 |
GO:004315418 | Oral cavity | LP | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 43/4623 | 78/18723 | 8.35e-09 | 3.31e-07 | 43 |
GO:200011719 | Oral cavity | LP | negative regulation of cysteine-type endopeptidase activity | 46/4623 | 86/18723 | 9.22e-09 | 3.61e-07 | 46 |
GO:000188919 | Oral cavity | LP | liver development | 62/4623 | 147/18723 | 2.32e-06 | 5.14e-05 | 62 |
GO:0048732110 | Oral cavity | LP | gland development | 149/4623 | 436/18723 | 4.51e-06 | 9.17e-05 | 149 |
GO:006100819 | Oral cavity | LP | hepaticobiliary system development | 62/4623 | 150/18723 | 5.13e-06 | 1.03e-04 | 62 |
GO:0043620110 | Oral cavity | LP | regulation of DNA-templated transcription in response to stress | 28/4623 | 53/18723 | 9.88e-06 | 1.80e-04 | 28 |
GO:0045861110 | Oral cavity | LP | negative regulation of proteolysis | 122/4623 | 351/18723 | 1.32e-05 | 2.34e-04 | 122 |
GO:004355512 | Oral cavity | LP | regulation of translation in response to stress | 14/4623 | 20/18723 | 2.51e-05 | 4.04e-04 | 14 |
GO:001604918 | Oral cavity | LP | cell growth | 155/4623 | 482/18723 | 1.08e-04 | 1.31e-03 | 155 |
GO:000155817 | Oral cavity | LP | regulation of cell growth | 134/4623 | 414/18723 | 2.25e-04 | 2.41e-03 | 134 |
GO:001046619 | Oral cavity | LP | negative regulation of peptidase activity | 87/4623 | 262/18723 | 1.12e-03 | 9.19e-03 | 87 |
GO:005134619 | Oral cavity | LP | negative regulation of hydrolase activity | 120/4623 | 379/18723 | 1.16e-03 | 9.48e-03 | 120 |
GO:001095118 | Oral cavity | LP | negative regulation of endopeptidase activity | 83/4623 | 252/18723 | 1.86e-03 | 1.39e-02 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS6KA1 | SNV | Missense_Mutation | novel | c.107G>T | p.Gly36Val | p.G36V | Q15418 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
RPS6KA1 | SNV | Missense_Mutation | novel | c.732C>A | p.Asn244Lys | p.N244K | Q15418 | protein_coding | tolerated(0.11) | benign(0.113) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RPS6KA1 | SNV | Missense_Mutation | rs768720668 | c.1195N>A | p.Asp399Asn | p.D399N | Q15418 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
RPS6KA1 | SNV | Missense_Mutation | | c.908N>A | p.Arg303Gln | p.R303Q | Q15418 | protein_coding | tolerated(0.17) | benign(0.179) | TCGA-EW-A1IY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
RPS6KA1 | SNV | Missense_Mutation | rs766116930 | c.1397N>T | p.Ser466Leu | p.S466L | Q15418 | protein_coding | deleterious(0.01) | benign(0.199) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
RPS6KA1 | insertion | Frame_Shift_Ins | novel | c.988_989insGTTTC | p.Tyr330CysfsTer68 | p.Y330Cfs*68 | Q15418 | protein_coding | | | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
RPS6KA1 | insertion | Nonsense_Mutation | novel | c.989_990insGGGCGAAGCTAGGCATGCCCCAGTTT | p.Tyr330Ter | p.Y330* | Q15418 | protein_coding | | | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
RPS6KA1 | SNV | Missense_Mutation | novel | c.154G>A | p.Glu52Lys | p.E52K | Q15418 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPS6KA1 | SNV | Missense_Mutation | rs779751417 | c.1207N>T | p.Arg403Cys | p.R403C | Q15418 | protein_coding | tolerated(0.06) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA1 | SNV | Missense_Mutation | novel | c.1016N>G | p.Tyr339Cys | p.Y339C | Q15418 | protein_coding | tolerated(0.06) | benign(0.054) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 | | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 385612197 | | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 | | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565718 | CHEMBL573107 | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 178101606 | DORSOMORPHIN | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565843 | | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | Pyrrolo[2,3-d]pyrimidine derivative 2 | | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | BI-D1870 | CHEMBL573107 | |
6195 | RPS6KA1 | SERINE THREONINE KINASE, KINASE, ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | | Pyrrolo[2,3-d]pyrimidine derivative 1 | | |